In conclusion, G-CSF administered 10 μg/kg daily for five days appeared to be safe and well tolerated in five patients aged 35–75 years with acute ischemic stroke in accordance with other published G-CSF trials in stroke patients. The gene discussed is CSF3; the disease is stroke disorder.